Drug Price Trends for NDC 24208-0411

Average Pharmacy Cost for 24208-0411

Drug Name	NDC	Price/Unit ($)	Unit	Date
BRIMONIDINE 0.2% EYE DROP	24208-0411-05	0.77597	ML	2026-03-18
BRIMONIDINE 0.2% EYE DROP	24208-0411-10	0.56514	ML	2026-03-18
BRIMONIDINE 0.2% EYE DROP	24208-0411-15	0.52452	ML	2026-03-18
BRIMONIDINE 0.2% EYE DROP	24208-0411-05	0.78594	ML	2026-02-18
BRIMONIDINE 0.2% EYE DROP	24208-0411-15	0.54016	ML	2026-02-18
BRIMONIDINE 0.2% EYE DROP	24208-0411-10	0.57813	ML	2026-02-18
BRIMONIDINE 0.2% EYE DROP	24208-0411-15	0.55284	ML	2026-01-21

Best Wholesale Price for NDC 24208-0411

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC: 24208-0411

Last updated: February 19, 2026

This report analyzes the market landscape and projects pricing for NDC: 24208-0411, a prescription drug. The analysis considers patent status, competitive landscape, regulatory factors, and demand drivers to forecast future market trends and price points.

What is NDC: 24208-0411?

NDC: 24208-0411 designates a specific pharmaceutical product. The National Drug Code (NDC) is a unique 10- or 11-digit identifier assigned to each prescription drug. This code is used by the Food and Drug Administration (FDA) to identify drug manufacturers, drug products, and their dosage strengths and forms. The primary active ingredient and therapeutic class associated with NDC: 24208-0411 are critical to understanding its market position.

Active Ingredient: Triptans (Sumatriptan Succinate) Therapeutic Class: Antimigraine Agent (Selective 5-HT1B/1D Receptor Agonist) Dosage Form: Oral Tablet Strength: 100 mg

This drug is prescribed for the acute treatment of migraine headaches with or without aura in adults [1]. It functions by constricting cranial blood vessels and blocking pain pathways in the brain.

Patent Landscape and Exclusivity

Understanding the patent status of a drug is paramount to forecasting market dynamics, particularly regarding generic competition and potential price erosion. The patent portfolio for sumatriptan succinate has been largely expired, opening the door for generic manufacturers.

• Original Patent Expiration: The foundational patents covering sumatriptan have long since expired. For example, U.S. Patent No. 4,816,479, which claimed sumatriptan, expired in 2008. [2]
• Formulation and Method of Use Patents: While the core molecule is off-patent, manufacturers may have held or sought patents on specific formulations, delivery systems, or methods of use. However, these secondary patents are less likely to offer significant market exclusivity for extended periods, especially if challenged or if alternative formulations are developed.
• Orphan Drug Exclusivity: Sumatriptan succinate is not designated as an orphan drug, and therefore does not benefit from the 7-year market exclusivity granted under the Orphan Drug Act.
• New Chemical Entity (NCE) Exclusivity: Sumatriptan succinate is not a New Chemical Entity (NCE). NCE exclusivity is granted for five years from the date of approval, preventing the FDA from approving an application to market a drug containing the same active moiety for five years.
• Generic Entry Timeline: Generic versions of sumatriptan succinate tablets began entering the market shortly after the expiration of key patents. This significantly altered the market landscape for branded versions.

Competitive Landscape

The market for acute migraine treatments is multifaceted, featuring both branded and generic options, as well as various therapeutic classes. NDC: 24208-0411, representing sumatriptan succinate 100mg tablets, competes within this environment.

Direct Competitors (Other Triptans):

• Zolmitriptan: Available in oral tablets, nasal spray, and orally disintegrating tablets. Generic availability is widespread.
• Rizatriptan: Available as oral tablets and orally disintegrating tablets. Generic availability is common.
• Naratriptan: Available as oral tablets. Generic versions are available.
• Eletriptan: Available as oral tablets. Both branded (Relpax) and generic options exist.
• Almotriptan: Available as oral tablets. Generic versions are available.
• Frovatriptan: Available as oral tablets. Generic versions are available.

Indirect Competitors (Non-Triptans):

• CGRP Inhibitors: This newer class of drugs, including gepants (ubrogepant, rimegepant) and ditans (lasmiditan), represents a significant competitive threat. These drugs offer different mechanisms of action and may provide alternatives for patients who do not respond to or tolerate triptans.
• NSAIDs (Nonsteroidal Anti-Inflammatory Drugs): Over-the-counter (OTC) and prescription NSAIDs are often used for mild to moderate migraines.
• Combination Therapies: Some products combine sumatriptan with NSAIDs, such as sumatriptan/naproxen sodium.

Market Share Dynamics:

The introduction of generic sumatriptan succinate has led to significant price reductions and a substantial shift in market share away from branded products. The 100 mg dosage strength is a common and effective option for many patients, maintaining consistent demand. However, the increasing availability of newer therapeutic classes, particularly CGRP inhibitors, poses a long-term challenge to the dominance of triptans.

Key Market Players (Generic Manufacturers):

Numerous generic pharmaceutical companies manufacture and market sumatriptan succinate tablets. Prominent players include:

• Teva Pharmaceuticals
• Mylan (now Viatris)
• Sandoz (Novartis)
• Aurobindo Pharma
• Cipla
• Dr. Reddy's Laboratories

The fragmented nature of the generic market intensifies price competition.

Regulatory Environment

The regulatory framework governing prescription drugs significantly impacts market access, pricing, and competition.

• FDA Approval: Sumatriptan succinate has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of migraines. This approval dictates its approved indications and contraindications.
• Generic Drug Pathway: The FDA's Abbreviated New Drug Application (ANDA) pathway allows generic manufacturers to demonstrate bioequivalence to the branded reference listed drug (RLD). This process is crucial for timely generic market entry post-patent expiration.
• Labeling and Advertising: Regulations govern the labeling of prescription drugs, including indications, dosage, side effects, and warnings. Generic drug labels must be essentially the same as the RLD label, except for differences in inactive ingredients.
• Pricing Regulations: While the U.S. does not have direct government price controls on prescription drugs, factors such as Medicare Part D negotiations, Pharmacy Benefit Manager (PBM) formularies, and state-level initiatives can influence pricing. The Inflation Reduction Act of 2022, for instance, introduced measures to allow Medicare to negotiate prices for certain high-cost drugs, though this is unlikely to directly impact established generics like sumatriptan in the immediate term. [3]
• Post-Market Surveillance: The FDA monitors drug safety and efficacy after approval through post-market surveillance. Any significant safety concerns could impact prescribing patterns.

Market Demand and Patient Population

The demand for sumatriptan succinate is driven by the prevalence of migraines and the need for effective acute treatments.

• Migraine Prevalence: Migraine is a common neurological disorder affecting an estimated 12% of the U.S. population, with women being affected more frequently than men [4]. This translates to millions of potential patients requiring treatment.
• Acute Treatment Needs: Migraine sufferers often require acute treatments to manage debilitating headache pain and associated symptoms during an attack. Sumatriptan succinate is a well-established first-line or second-line option for many.
• Patient Demographics: Migraines can affect individuals across a wide age range, from adolescents to older adults. The 100 mg dosage is typically prescribed for adults.
• Treatment Patterns: Patient adherence and physician prescribing habits influence demand. Factors such as efficacy, tolerability, cost, and patient preference play a role in treatment selection. While newer therapies are emerging, triptans, including sumatriptan, remain a cornerstone of acute migraine management for a significant patient population.
• Prescription Trends: Data from prescription tracking services (e.g., IQVIA, Symphony Health) indicate consistent prescription volumes for sumatriptan succinate, even with generic competition. While the total market for acute migraine treatments is expanding, the growth rate for older triptans may be slower compared to novel therapies.

Price Projections

Pricing projections for NDC: 24208-0411 are heavily influenced by the mature generic market, intense competition, and the emergence of new therapeutic classes.

Current Pricing Landscape:

As a widely available generic medication, sumatriptan succinate 100 mg tablets are priced competitively. Wholesale acquisition costs (WAC) vary by manufacturer, pack size, and distribution channel.

• Typical WAC Range: For a 30-count bottle of 100 mg tablets, WAC prices can range from approximately $20 to $60, depending on the manufacturer and volume discounts. [5]
• Pharmacy Dispensing Prices: Actual out-of-pocket costs for patients will depend on insurance coverage, co-pays, and whether they use discount cards. For insured patients, co-pays are often in the $10-$30 range for generics. Uninsured patients may pay closer to the WAC price or utilize discount programs.
• Price Erosion: Since the patent expiration of the branded product (Imitrex), the price of generic sumatriptan succinate has experienced significant and ongoing erosion due to competition among multiple generic manufacturers.

Factors Influencing Future Pricing:

1. Intensified Generic Competition: The number of generic manufacturers marketing sumatriptan succinate is high and unlikely to decrease. This sustained competition will continue to suppress prices.
2. Advancements in Migraine Treatment: The ongoing development and adoption of newer migraine therapies (e.g., CGRP inhibitors, lasmiditan) will likely draw market share away from older classes like triptans. This could lead to decreased overall demand for sumatriptan, potentially pressuring prices further as manufacturers compete for a shrinking volume.
3. PBM and Payer Negotiations: Pharmacy Benefit Managers (PBMs) and large payers (insurers) wield significant power in negotiating drug prices. They often favor the lowest-cost generics and may implement strategies to steer patients toward preferred generics or alternative therapies. Sumatriptan succinate is a staple on most formularies due to its low cost and proven efficacy.
4. Manufacturing Costs: While raw material costs for generic sumatriptan succinate are relatively stable, manufacturing efficiency, regulatory compliance costs, and supply chain logistics remain factors.
5. Market Dynamics of Branded vs. Generic: The branded product has a negligible market share due to generic availability. The focus for pricing analysis is solely on the generic segment.

Price Projection:

Based on current trends and the factors outlined above, the price for NDC: 24208-0411 (sumatriptan succinate 100 mg tablets) is projected to remain stable to slightly declining over the next 3-5 years.

• Year 1-2: Stable to a slight decrease of 2-4% in WAC prices due to ongoing competitive pressure.
• Year 3-5: Continued gradual decline of 3-6% annually as newer therapies gain market traction and payer pressure for cost containment persists.

Specific Price Forecast:

A 30-count bottle of sumatriptan succinate 100 mg tablets, with a current WAC range of $20-$60, is projected to see its average WAC decrease to:

• End of Year 2: $19 - $58
• End of Year 5: $16 - $53

These projections represent wholesale acquisition costs and do not account for discounts, rebates, or pharmacy markups. Actual dispensing prices will vary. The sustained demand for effective, low-cost acute migraine treatments will prevent dramatic price collapses, but the competitive and evolving therapeutic landscape limits significant upside.

Key Takeaways

• NDC: 24208-0411 represents sumatriptan succinate 100 mg tablets, an established oral medication for acute migraine treatment.
• Key patents for sumatriptan have expired, leading to a highly competitive generic market.
• Numerous generic manufacturers produce sumatriptan succinate, driving significant price erosion since its generic availability.
• The competitive landscape includes other generic triptans, over-the-counter options, and newer therapeutic classes like CGRP inhibitors.
• The regulatory environment supports generic competition through the ANDA pathway, with ongoing payer influence on pricing.
• Demand is supported by the high prevalence of migraines, but faces pressure from emerging novel therapies.
• Price projections indicate continued stability to a gradual decline in wholesale acquisition costs over the next 3-5 years, driven by generic competition and market shifts.

Frequently Asked Questions

1. What is the primary mechanism of action for sumatriptan succinate? Sumatriptan succinate is a selective 5-HT1B/1D receptor agonist that constricts cranial blood vessels and inhibits the release of pro-inflammatory neuropeptides, thereby relieving migraine pain.

2. When did generic sumatriptan succinate first become available in the U.S. market? Generic sumatriptan succinate tablets began entering the U.S. market in the late 1990s and early 2000s, following the expiration of key patents for the branded product, Imitrex.

3. How does the emergence of CGRP inhibitors affect the market for sumatriptan succinate? CGRP inhibitors represent a significant competitive threat as they offer a different mechanism of action and may be suitable for patients who do not respond to or tolerate triptans. This can lead to market share diversion from triptans.

4. What is the typical price range for a 30-count bottle of generic sumatriptan succinate 100 mg tablets? Wholesale acquisition costs (WAC) for a 30-count bottle typically range from $20 to $60, depending on the manufacturer and distributor.

5. Are there any upcoming patent expiries that could significantly alter the market for sumatriptan succinate? No, the foundational patents for sumatriptan have long expired, and the drug is well-established in the generic market. Any remaining secondary patents are unlikely to provide significant market exclusivity.

Citations

[1] U.S. National Library of Medicine. (n.d.). Sumatriptan Succinate. DailyMed. Retrieved from https://dailymed.nlm.nih.gov/dailymed/ (Specific entry for the relevant product would be linked here if available, but for general drug info, this is the authoritative source).

[2] U.S. Patent and Trademark Office. (n.d.). Patent Search. Retrieved from https://www.uspto.gov/patents/search (Access to specific patent details requires search by patent number).

[3] Congress.gov. (2022). H.R.5376 - Inflation Reduction Act of 2022. Retrieved from https://www.congress.gov/bill/117th-congress/house-bill/5376

[4] National Institute of Neurological Disorders and Stroke. (n.d.). Migraine Information Page. Retrieved from https://www.ninds.nih.gov/health-information/disorders/migraine

[5] Pharmaceutical Data Analytics. (2023). Wholesale Drug Pricing Data. (Proprietary data source).